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Objective: Allograft-targeted immunosuppressive gene therapy may inhibit 
recipient immune activation and provide an alternative to systemic immu- 
nosuppression. We studied the optimal technique and efficacy of intracoro- 
nary gene transfer of viral interleukin-10 and human transforming growth 
factor-101 in a rabbit model of heterotopic heart transplantation. Methods: 
Replication-defective adenoviral vectors were constructed, expressing 
viral interleukin-10 (AdSvIL10) or transforming growth factor-/31 
(AdCMVTGF-~I). Intracoronary delivery of vectors was accomplished ex 
vivo by either bolus injection or slow infusion. The allografts were im- 
planted heterotopically in recipient rabbits and collected 4 days after the 
operation. Vector dose was 4 x 109 to 6 x 10 TM pfu/gm of donor heart. 
Transfer was confirmed by DNA amplification for both genes. Gene product 
expression in tissue was quantified by immunoassay and visualized by 
immunohistochemical staining. Results: Allograft viral uptake was only 
9.9% --- 2.4% with bolus injection, but increased to 80.5% --- 6.8% at 1 
ml/min infusion rate (p = 5 x 10-14). Uptake ratio was not affected by 
vector quantity or slower infusion rates. Transforming rowth factor-~l 
was consistently detected in allografts infected with AdCMVTGF-~I , but 
not with control adenovirus or AdSvlL10. Expression was proportional to 
infused vector quantity and reached 10 ng/gm of allograft at infused 10 TM 
pfu/gm. Transforming rowth factor-j31 was also detected in recipient's 
serum at less than 1 ng/ml. Viral interleukin-10 was detected in minor 
amounts only (<1 ng/gm) in allografts infected with AdvIL10 up to 5 x 10 TM 
pfu/gm. Nevertheless, it was detected in recipient serum at concentrations 
up to 0.4 ng/ml. Conclusions: Intracoronary gene transfer of immunosup- 
pressive cytokines to cardiac allografts during cold preservation is feasible. 
Slow infusion is superior to bolus injection. In vivo effects on allograft 
rejection remain to be determined. (J Thorac Cardiovasc Surg 1997;113: 
i059-67) 
T he ability of myocardial cells to uptake and express foreign recombinant DNA constitutes 
the basis for allograft-targeted gene therapy. A 
potential application is local modulation of the host 
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immune response by the genetically modified allo- 
graft, hence offering an alternative to nonspecific 
systemic immunosuppression. Theoretically, soluble 
proteins secreted within the transplanted organ 
should be able to exert a local in vivo effect, without 
requiring expression in all target cells. This strategy, 
however, depends on efficient gene transfer into 
donor hearts. Although successful transfer of re- 
porter genes into intact hearts has been accom- 
plished by direct myocardial injection, this method 
may result in uneven distribution, and inflammation 
at the sites of injection was reported. 1'2 Recently, 
the feasibility of intracoronary delivery of reporter 
genes to allografts during cold preservation has been 
demonstrated, utilizing cationic liposomes 3'4 and 
adenoviral vectors. 5 
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Adenoviral vectors are the most effective vehicle 
for gone transfer, having a high affinity for the 
myocardium 6 and the ability to infect nonreplicating 
cells at low temperature.  7 For this study we used a 
first-generation mutant of the widespread type 5 
adenovirus, which has been rendered replication- 
deficient by deletions of early viral protein-encoding 
sequences. 8 
Two multifunctional cytokines hold promise as 
candidates for immunosuppressive g ne therapy in 
vivo, both having potent inhibitory functions in 
critical pathways of alloreactivity. Interleukin-10 
(IL-10), an 18 kd polypeptide, is a down-regulator of 
cytokine synthesis by Thl cells activated by mono-  
cyte-macrophage antigen-presenting cells. It inhibits 
monocyte -macrophage-dependent  T-cell activation 
and antigen-presenting cell function, 9' 10 and has 
been shown to suppress alloreactivity in vivo. 11 A 
viral homologue of IL-10 was used in this study. This 
protein is a product of the Epstein-Barr virus 
BCRF1 gone 12 and shares most of the biologic and 
immunologic propert ies of the cellular cytokine, t3 
Transforming rowth factor-/3 t (TGF-/3t) is a ubiq- 
uitous 25 kd homodimer  with extensive regulatory 
functions. 14 It has multiple effects on the immune 
system that include inhibition of natural killer activ- 
ity, T- and B-cell prol iferation and cytokine produc- 
tion. 15 Systemically administered TGF-13a has been 
shown to prolong survival of heterotopic rat cardiac 
allograftsJ 6
This study evaluated the feasibility of intracoro- 
nary transfer of these functional cytokine genes into 
cardiac allografts at the time of cold preservation. 
We examined the optimal method of vector delivery 
and the magnitude and distribution of resulting 
transgene xpression. 
Materials and methods 
Viral vectors. Adenovirus type 5 mutants were con- 
structed by the authors (L.W., A.B.). Deletions of the 
entire E la and most of the Elb regions (early viral 
proteins) render the vector (Ad5d1434) infectious but 
replication-defective. The deleted sequences were re- 
placed by corresponding cDNA expression cassettes: For 
viral IL-10 (AdSvIL10), the SV40 promoter/enhancer 
drives the Epstein-Barr BCRF1 gone and a polyadenyla- 
tion signal. In TGF-/31-encoding vectors (AdCMVTGF- 
/31), the human active TGF-/3~ cDNA is under the control 
of the cytomegalovirus intermediate early promoter. Viral 
stocks were grown in embryonic kidney (293) cells that 
constitutively express E1 proteins and stored at -70 ° C. 
Viral titers were determined by plaque assays on mono- 
layer 293 celIs and expressed as plaque-forming units per 
milliliter (pfu/ml). To confirm the ability of the vectors to 
express the encoded transgenes. 293 cells were infected 
and culture supernatant was assayed 24 hours after infec- 
tion for both encoded proteins. 
Rabbits. New Zealand White donor rabbits weighing 
1.7 to 2 kg l Charles River Laboratories, St. Constant. 
Quebec. Canada l and recipients weighing 5 to 5.5 kg 
(Irish Farms. Norco. Calif.I were purchased from geo- 
graphically unrelated vendors. All animals received hu- 
mane care m compliance with the "Principles of Labora- 
tory Animal Care" formulated by the National Society for 
Medical Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23; revised 
1985). 
Animal management. Anesthesia was induced intrave- 
nously with ketamine (10 mg/kg) and acepromazine (1 
mg/kg) and maintained with inhaled 1.5% isoflurane in 
oxygen via mechanical ventilation. Heparin (200 U/kg) 
was given intravenously to both donors and recipients. 
Recipients received cefazolin (40 mg kg) before incision. 
Donor heart harvest. After sternotomy, systemtc ve- 
nous return to donor hearts was occluded, the pulmonary 
artery was transected, and the aorta was crossclamped. 
University of Wisconsin solution (15 ml) was injected into 
the proximal aorta and topical cooling was applied. The 
pulmonary veins were then ligated and the heart was 
excised and placed in cold (4 ° C) University of Wisconsin 
solution. 
Intraeoronary gone transfer, During preservation at 
4 ° C. the donor aorta was cannulated. Viral vectors resus- 
pended in 20 ml University of Wisconsin solution were 
administered by either fast injection or slow infusion at 1 
and 0.5 ml'min. After administration of at least 10 ml, 
coronary sinus effluent was collected for determination of
viral titers. Total quantity of infused virus was 4 × 109 to 
6 x 10 l° pfu/gm of donor heart. 
Transplantation. Donor hearts were transplanted in 
the heterotopic ervical position. The donor aorta and 
pulmonary artery were anastomosed to the recipient's 
right carotid artery and jugular vein. respectively. The 
recipient distal carotid artery was ligated. Topical cooling 
of donor hearts was maintained throughout he proce- 
dure. Average ischemic time was 55 minutes with bolus 
injection and 75 minutes with intracoronary delivery at a 
rate of i ml/min. Additional grafts were perfused at a rate 
of 0.5 ml/min (n = 3, ischemic time - 100 minutes) or 
preserved for 2 hours after bolus injection (n = 3, 
ischemie time = 160 minutes). All allografts resumed 
spontaneous vigorous contraction within minutes of 
reperfusion. All recipients survived the procedure and 
were allowed to recover. Allografts were inspected aily 
by direct palpation. Cessation of mechanical activity be- 
fore day 4 (in 5%) was considered the result of technical 
failure. 
Specimen preparation. Normally contracting rafts, re- 
cipient native hearts, and serum samples were collected 
on postoperative day 4. Transmural specimens from the 
left and right ventricular free walls and intraventricular 
septum were frozen in liquid nitrogen. 
Polymerase chain reaction. Flanking primers were de- 
signed for internal regions of both transgenes: for viral 
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IL-10, a 461 bp region (sense: 5'-ATGGAGCGAAGGT- 
TAGTGGTC A-3'; antisense: 5'-CCTGGCTTTAATT- 
GTCATGTATGCT-3'); for TGF-/31, a 243 bp region 
(sense: 5'-GCCCTGGACACCAACTATTGC-3'; anti- 
sense: 5'-TTGCGGCCCACGTAGTACA-3'). 
DNA was extracted from frozen specimens by the 
proteinase K incubation method. In brief, samples were 
crushed to fine powder and suspended in digestion buffer 
(sodium chloride, 100 retool/L; tromethamine chloride, 10 
mmol/L; ethylenediaminetetraacetic acid,25 mmol/L; so- 
dium dodecylsulfate 0.5%; pH 8.0, proteinase K, 0.1 
mg/ml) at 80 ° C for 1 hour. Phenol/chloroform/isoamyl 
alcohol (25:24:1) was added in equal volumes, and then 
the upper aqueous phase was separated by centrifugation. 
This step was repeated with and without chloroform; then 
2 volumes of 100% ethanol and 10% sodium acetate (pH 
5.2) were added at -20 ° C for 1 hour. DNA precipitate was 
dried and resuspended in water at room temperature. 
Polymerase chain reaction (PCR) was performed in a 
DNA thermal cycler (Perkin-Elmer, Norwalk, Conn.) and 
consisted of 30 cycles (denaturing: 94 ° C-I', annealing of 
primers: 55 ° C-1', and extension: 72 ° C-1'). PCR products 
were separated by electrophoresis in 1.2% agarose gel, 
then stained with ethidium bromide. The original expres- 
sion plasmids used for vector construction (pAdSvIL10 
and pAdCMVTGF) served as positive controls. 
Immunoassay. Heart protein was extracted from fro- 
zen specimens by homogenization in tromethamine chlo- 
ride 50 mmol/L, sodium chloride 150 mmol/L, 5%/3-mer- 
captoethanol, ethylenediaminetetraacetic acid 2 mmol/L, 
and phenylmethylsulfonyl fluoride 1 mmol/L, with leupep- 
tin 25 pg/ml, TPCK 10 p~g/ml, TLCK 10 /xg/ml, E64 5 
p~g/ml, and antipain 5 /xg/ml, at 1:3 dilution. Protein 
extract was stored in liquid nitrogen. A double-antibody 
capture enzyme-linked immunosorbent assay (ELISA) 
was used to quantify cytokines in protein extract. 
Recombinant viral IL-10. Standard 96-well flat-bottom 
plates were coated overnight at 4 ° C with 50/xl monoclo- 
hal rat antihuman/viral IL-10 antibody (Pharmigen), then 
washed two times with phosphate-buffered saline/Tween 
solution and blocked with phosphate-buffered saline solu- 
tion/10% fetal calf serum for 1 hour. After being washed 
two times, standard, samples, and controls were added for 
2 hours at room temperature. Standard curves were 
generated with the use of recombinant human IL-10 
(kindly provided by Dr. Kevin Moore, DNAX, Palo Alto, 
Calif.). After the sixth wash, 100/4 secondary biotinylated 
monoclonal rat antihuman/viral IL-10 antibody (Pharmi- 
gen) was added at room temperature for 45 minutes, then 
washed six times. Avidin peroxidase was added for 30 
minutes, washed eight times, and then 0.1% hydrogen 
peroxide in ABTS substrate was used to visualize detec- 
tion. Viral culture supernatants from AdSvIL10-infected 
293 cells served as positive controls. 
Recombinant TGF./~ 1. A human TGF-/31 ELISA de- 
tection kit (Genzyme, Cambridge, Mass.) with 50 pg/ml 
sensitivity was used. The kit includes 96-well plates pro- 
coated with monoclonal mouse antihuman TGF-/31. Stan- 
dard recombinant human TGF-/31 samples and controls 
were activated in 1N hydrogen chloride, added to the wells 
for 1 hour at 37 ° C, then washed five times. Detecting 
anti-TGF-/3 s histidine-rich protein conjugate was added 
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Fig. 1. Fraction viral vectors absorbed by allografts using 
bolus injection (left) and slow intracoronary infusion 
(right). Values are expressed as mean _+ 95% confidence 
intervals. The difference is highly significant (p = 5 × 
10-14: Two-tailed Student's t test). 
for 1 hour at 37 ° C, then washed five times. A color 
reaction was obtained by adding 2% tetramethylbenzidine 
and 0.03% hydrogen peroxide for 20 minutes at room 
temperature. Viral culture supernatants from sense and 
antisense AdCMVTGF-/31-infected 293 cells served as 
positive and negative controls. 
Quantification was performed on an automated 
ELISA plate reader (Dynatech Laboratories) at 450 
nm. Results are expressed in nanograms per gram of 
allograft issue. 
TGF-/~ 1 immunohistochemieal staining. Frozen speci- 
mens were cryosectioned at5/zm thickness, fixed in 10% 
tromethamine-buffered formalin for 12 minutes at 4 ° C, 
then rinsed with triethanolamine-buffered saline solution. 
Endogenous peroxidase activity was quenched by 3% 
hydrogen peroxide. Unspecific binding was blocked with 
10% normal chicken serum and 0.2% bovine serum 
albumin in triethanolamine-buffered saline solution. The 
sections were then incubated overnight with 1:500 chicken 
purified (polyclonal) antihuman TGF-/31 (R&D Systems, 
Minneapolis, Minn.) in a humidified chamber at 4 ° C. A 
biotinylated goat antichicken antibody and streptoavidin- 
peroxidase complex (Vector Laboratories, Burlinghame, 
Calif.) were used for detection of bound primary antibod- 
ies. Immunocomplexes were visualized by aminoethylcar- 
bazole and 0.3% hydrogen peroxide. The sections were 
counterstained with hematoxylin. Incubation with chicken 
preimmune serum at the same dilution, as well as omis- 
sion of the primary antibody, did not result in positive 
staining, thus demonstrating specificity. 
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Fig. 2. At a delivery rate of 1 ml/min, the correlation between infused and absorbed vector quantity is 
linear (p < 10 -4, Pearson's correlation). There is no decline in absorbed quantity at maximal infused 
quantity up to 6 × 101° pfu/gm. 
Results 
Allograft viral uptake. Average allograft single- 
pass viral uptake was only 9.9% _+ 2.4% with bolus 
injection. At intracoronary infusion rates of 1 ml/ 
min or 0.5 ml/min, maximal uptake was 91% 
(mean = 80.5% -+ 6.8%,p = 5 × 10 -14, Student's t 
test) (Fig. 1). Ratio uptake by allografts was constant 
with total infused viral quantity ranging from 4 × 
109 to 6 × 101° pfu/gm of donor heart. With slow 
infusion, the correlation of absorbed and infused 
quantity of vectors was linear and highly significant 
throughout he range (Pearson correlation, two- 
tailed coefficient r = 0.994, p < 10 -4) (Fig. 2). 
PCR. PCR was performed on grafts infected by 
intracoronary infusion at a rate of 1 ml/min. Gene 
transfer was confirmed by demonstration f the pres- 
ence of both inserted genes in DNA extract from 
corresponding allografts but not controls (Fig. 3). 
TGF-/] 1 expression. Significant TGF-/31 protein 
expression was detected in all allografts infected 
with AdCMVTGF-/31 at a rate of i ml/min (n = 10). 
Average level was 3.1 _+ 1.5 ng/gr (range 0.7 to 10 
ng/gr). In contrast, only minimal TGF-/31 expression 
was found in AdSvlL10 or control virus-infected 
allografts (n = 10, mean = 0.32 _+ 0.15 ng/gr, p < 
10 -4, Mann-Whitney U test). Similarly, grafts in- 
fected with bolus-injected AdCMVTGF-/31 at 101° 
pfu/gm (n = 3) did not express TGF-/31 above control 
levels. Breakdown of TGF-/31 expression in the left 
and right ventricles and intraventricular septum is 
shown in Fig. 4. Although the differences in protein 
levels among the different regions are not significant. 
expression i  the right ventricle was lower than in the 
left ventricle and septum in nine of ten tested samples 
(p = 0.022, related-samples exact sign test). A corre- 
lation between TGF-/31 expression and the quantity of 
infused vectors (p - 0.044. Pearson correlation, two- 
tailed) was observed (Fig. 5). TGF-/31 was also de- 
tected in the serum of AdCMVTGF-/31 recipients at 
concentrations of 0.05 to 1 ng/mt, but not in controls. 
In the supernatant of infected 293 cells. TGF-/31 levels 
were >30 ng/ml. 
IL-10 expression. The sensitivity of viral IL-10 
ELISA was 30 p&ml. Viral IL-10 was detected only 
in graft protein extract and recipient serum from 
allografts infected by slow (1 ml/min) infusion of 
AdSvIL10 at 10 l° to 6 × 10 l° pfu/gm (n - 3). Tissue 
levels ranged from 50 to 900 pg/gm (mean -- 300 
pg/gm) and serum levels were 330 to 390 pg/ml. 
Viral IL-10 was not detected in allografts or serum 
infected with AdSvlL10 at <10 l° pfu/gm (n = 7), 
control virus, native hearts, or grafts infected with a 
bolus-injected AdSvIL10 dose of 2 × 10 l° pfu/gm 
(n - 3). Preservation of the grafts for 2 hours before 
implantation did not result in detectable viral IL-10 
expression in the bolus-injected grafts (n = 3). 
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Fig. 3. PCR analysis of transgene sequences in DNA 
extract from representative allografts and in control plas- 
mids: Lane 1, A graft infected with the control vector 
Ad5d1434 isnegative for both sequences. Lane 2, A graft 
infected with the AdSvIL10 is positive for the expected 
461 bp fragment. Lane 3, The plasmid pAdSvIL10 was the 
positive control for the viral IL-10 gene. Lane 4, Ladder 
marker. Lane 5, The plasmid pAdCMVTGF served as a 
positive control for detection of the expected 243 bp 
human TGF-]31 gene fragment. Lane 6, A graft infected 
with the AdCMVTGF-/31 vector. 
Levels of viral IL-10 in the supernatant of infected 
293 cells were up to 17 ng/ml. 
TGF-/31 immunohistochemistry. Specific TGF-/31 
staining was observed in AdCMVTGF-/31-infected 
allografts (Fig. 6). Significant TGF-/31 expression 
was present in the extracellular matrix as well as 
myocytes and seemed to be more prominent in 
subepicardial regions. 
Discussion 
The current study constitutes a first attempt o 
construct an efficient system for intracoronary deliv- 
ery of functional genes to cardiac allografts during 
cold preservation. The long-term goal of this exper- 
iment is to achieve xpression of the inserted genes 
in quantities ufficient o modulate host immune 
responses in vivo. 
Several studies uggest that efficient ransduction 
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Fig. 4. Regional distribution of TGF-/31 expression i left 
and right ventricles and intraventricular septum. The differ- 
ence between AdCMVTGF-/31-infected hearts and controls 
is statistically significant in all areas (p < 0.01, two-tailed 
Student's t test). Expression i  the right ventricle was con- 
sistently lowest (p = 0.022, related-samples exact sign test). 
LV, Left ventricle; Sep, septum; RV, right ventricle. 
of allografts may actually prolong graft survival in 
vivo. Systemic administration of recombinant hu- 
man TGF-/31 has been shown to prolong survival of 
cardiac allografts in the rat. 16 IL-10 has also been 
shown to suppress alloreactivity in an in vivo mod- 
el. 11 Qin and associates 17' 18 recently reported effi- 
cient transfer of the viral IL-10 and TGF-]31 genes in 
nonperfused neonatal mouse cardiac allografts. Us- 
ing direct myocardial injection of plasmid or retro- 
viral expression vectors with various promoters, they 
achieved significant prolongation of allograft sur- 
vival with both transgenes. 
Replication-defective adenoviral vectors are cur- 
rently the most efficient vehicle for gene transfer 
into nondividing cells such as myocytes. The viral 
particle attaches to a variety of mammalian cells 
through specific membrane integrin receptors, then 
enters the cell by endocytosis. Up to 80% of inter- 
nalized viral particles reach the nucleus, where the 
viral genome remains episomal, thus resulting in 
transient expression. Exogenous DNA up to 8.3 kb 
can be used to replace the early expression regions 
El, E3, and optionally E4. Viral stocks for in vivo 
gene transfer can be grown at very high titers, s
Although the use of viral vectors in vivo raises safety 
concerns, the widespread type 5 adenovirus has not 
been associated with any known malignant diseases 
and has been used for routine vaccination i  human 
beings with no apparent side-effects. 19 
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Fig. 5. TGF-/31 expression (averaged left and right ventricles and intraventricular septum) correlates with 
the quantity of infused vectors (p = 0.044, Pearson's correlation). 
Fig. 6. Immunohistochemical st ining for human TGF-t31 in grafts infected by slow intracorona~ infusion 
of adenoviral vectors at 1 ml/min (×200). a, Subepicardial rea in a graft infected with control vectors 
(Ad5d1434). b, Subepicardial rea in a graft infected with AdCMVTGF-/3 v Positive imnmnostaining 
appeared as red-brown granules. 
The ability of explanted hearts to uptake adeno- 
viral vectors injected into the coronary arteries 
during cold preservation at 4°C has been qualita- 
tively demonstrated in this laboratory. 5 The distri- 
bution of reporter gene expression included myo- 
cytes as well as vascular endothelium and smooth 
muscle cells, but the percentage of cells expressing 
the transgene appeared to be small. Higher trans- 
duction rates were achieved by catheter-mediated 
intracoronary infusion in intact animals at normal 
temperature. 2° The authors injected undiluted viral 
vectors at 1 ml/min, resulting in transgene xpres- 
sion in up to 32% of perivascular myocytes and 
100% of endothelial cells. No inflammation was 
noted in any of these regions. 
In the present study we determined the optimal 
method of intracoronary vector administration by 
calculating the absorbed fraction of viral vectors at 
various rates of delivery. Although this is by no 
means indicative of gene product expression in 
tissue or even internalization of the virus into cells° 
it allows for a qualitative comparison of the two 
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methods evaluated for vector delivery. It appears 
that fast injection at physiologic pressure results in 
inefficient (<10%) uptake of vectors during the one- 
pass cold coronary flush. This corresponds to in vitro 
data in which adenoviral vectors have been shown to 
require 30 minutes and 1 hour to infect 30% and 50% 
of cultured cells, respectively, at 4 ° C. 7 In contrast, up 
to 91% of diluted vectors were absorbed when infused 
at a rate of 1 rnl/min, and further reducing infusion 
rate to 0.5 ml/min did not result in higher uptake rates. 
We therefore used the slow-perfusion technique for 
delivery of immunosuppressive cytokine genes. This 
factor should be considered when attempting delivery 
of exogenous DNA, protein, or chemicals by intra- 
coronary infusion. 
The correlation between the quantity of infused 
and absorbed vectors was linear throughout he 
range of administered oses. This is encouraging, 
because a very high amount of vectors may be 
administered without saturating allograft receptors. 
We also found that the levels of transgene xpres- 
sion correlated with infused vector quantity, sug- 
gesting that higher expression may be achieved by 
incremental vector delivery. This finding is consis- 
tent with previous experience with reporter 
genes. 2° 
TGF-/31 expression was significant and averaged 
levels that have been shown to dramatically reduce 
lymphokine-activated killer activity and pore-form- 
ing protein mRNA expression in CD8+ T lympho- 
cytes in vitro, a major .pathway in alloreactMty. In 
addition, the induction and magnitude of T-cell 
cytotoxicity are significantly reduced by TGF-/31 
levels as low as 0.5 ng/ml. 15 The distribution of 
transgene xpression in different regions of donor 
hearts was also evaluated. In a recent study of 
liposome-mediated intracoronary gene transfer, 4 no 
difference was observed between reporter gene ex- 
pression in the right and left ventricles. Our data 
show slightly lower average xpression in the right 
ventricle when compared with the left ventricle or 
intraventricular septum. However, separate analysis 
of expression in individual allografts consistently 
shows lower expression in the right ventricle, this 
tendency being statistically significant. This can be 
explained by assuming that the rabbit right ventric- 
ular free wall is supplied in part by the left coronary 
system. If this is the case, a large amount of slowly 
infused vectors will be absorbed in the left ventricle 
and septum before reaching the right side of the 
heart. However, we do not have experimental sup- 
port for this hypothesis. 
Expression of viral IL-10 in allograft protein 
extract was disappointing. Viral IL-10 was specifi- 
cally detected in recipient serum and allografts when 
viral doses higher than 10 l° pfu/gm were used, albeit 
at minor levels. The possibility that vectors flushed 
from the graft coronary circulation at reperfusion 
may partly account for detectable gene expression i
the recipient serum cannot be ruled out. Our failure 
to detect protein expression in grafts perfused with 
viral quantities lower than 101° pfu/gm may be due 
to several factors: Promoter potency is known to 
vary among species, and a possible adverse host 
factor in this case cannot be ruled out. The SV40 
promoter is known to be modest relative to the 
cytomegalovirus promoter used with the TGF-/3t 
gene. It is even more likely that fast secretion of 
soluble viral IL-10 by myocytes, combined with short 
plasma half-life, reduces this cytokine's availability 
for detection] 3 While TGF-/3a receptors are present 
on all mammalian cells, the heart does not bind 
IL-10. This cytokine is thus largely secreted into the 
bloodstream, whereas a large proportion of TGF-/3x 
is stored at the cell surface and extracellular matrix, 
where it can be more readily detected. 
Despite these data, in vivo activity of both cyto- 
kines cannot be predicted on the basis of their levels 
in tissue alone. Prolongation of allograft survival 
may be achieved, although it is not likely to persist 
beyond the time course of transgene xpression. 
Currently, the chief shortcoming of in vivo adenovi- 
rus-mediated gene transfer is its limited time course, 
a factor that was not addressed in this study. Al- 
though significant expression is present for up to 2 
weeks in vivo, almost no residual protein is detected 
1 month after delivery, and repeat administration is 
relatively ineffective as a result of preimmuniza- 
tion. 21 Because this factor is determined by specific 
vector attributes, improved vehicles for gene ther- 
apy are constantly being developed, including sec- 
ond- and third-generation adenoviruses. 22'a3 Fur- 
ther study of the in vivo effect of this first-generation 
adenovirus-mediated g ne transfer is warranted and 
may provide a glimpse into the future of allograft- 
targeted gene therapy. 
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Discussion 
Dr. Scot H. Merrick (San Francisco, Calif.). Gene 
therapy is opening anew chapter and perhaps arevolution 
in the way we practice medicine in surgery. Transplant 
immunology is ideally suited for this technology, and Dr. 
Brauner and his colleagues are close to changing the 
therapeutic approach to early graft rejection. They are to 
be commended and encouraged, because this is a very 
complicated field, both technically and conceptually. 
I have several questions. First, I am concerned that your 
method of measuring transduction efficiency or the ability 
of the virus to insert its DNA into the target cell is only 
qualitative and not quantitative. Measuring the difference 
between the quantity of virus introduced into the coronary 
circulation and the amount recovered in the coronary 
sinus may not be accurate inasmuch as many viruses 
transiently adhere to the cell surface without actually 
entering the cell. Have you done any staining experiments 
to quantify the number of cells actually transduced by your 
virus vector? 
Dr. Brauner. The current experience with intracoro- 
nary gene transfer consists of four articles, all describ- 
ing the use of reporter genes (such as/3-galactosidase). 
The object of this work was not to use reporter genes, 
but obviously we cannot avoid that when performing a
gene transfer experiment. We did that using the slow 
infusion method, and we counted the number of cells 
expressing /3-galactosidase. A problem with this deliv- 
ery method is that expression is not evenly distributed 
within the myocardium. What probably happens is that 
the virus adheres to the first cell it encounters, and this 
is usually in the peripheral perivascular regions. Indeed. 
around these regions the efficacy was 100% every cell 
was infected, including endothelial, smooth muscle, and 
myocardial cells. As we progress toward the subendo- 
cardial regions, expression decreases to between 5% 
and 30%, depending on the viral dose used. This is a 
considerable amount, nevertheless. It is the best result 
so far from an intracoronary transduction study. One 
study (by Barr and associates 2°) using in vivo intracoro- 
nary delivery achieved a 32% transduction in the 
perivascular regions. I do not agree that what we did is 
not quantitative. 1 believe that direct measurements of 
protein levels in tissue are objective and can be com- 
pared with in vitro functional data, as opposed to 
reporter gene expression, which can only be compared 
with other results using the same gene. It is therefore a
good way to study the magnitude of expression but not 
to localize it. We did not address the distribution of 
transduction i this paper, only the general magnitude. 
Dr. Merriek. My next question concerns gene expres- 
sion. TGF-/3 and IL-10 were under the control of two 
different promoters, which may explain the observed 
differences in expression of these two genes. More impor- 
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tant, IL-10 had a very low transduction elficiency, a low 
tissue level, and a very high serum level. How can this be? 
Dr. Brauner. I now believe that the promoters are not 
the main reason for the difference in gene expression. 
Rather, the reason is that all cells in the heart (and 
practically every cell in the body) have receptors for 
TGF-/3, but there are no IL-10 receptors in the heart. 
IL-10 receptors are found in lymphoid tissue, such as 
Thl helper ceils and monocyte-macrophages. What 
happens is that when a TGF-/31 molecule is produced it 
adheres to cell membranes and is not rapidly secreted, 
allowing for easy detection. Produced IL-10 probably 
gets secreted promptly, and then it is gone. Also, the 
plasma half-life of IL-10 is short, less than 2 hours in 
human beings. I now believe this is the reason for the 
low IL-10 detection in tissue, not that it is not pro- 
duced. I believe that with any adenovirus, using similar 
quantities of vector should result in similar quantities of 
transgene xpression. Indeed, the Sv40 promoter is less 
potent than the cytomegalovirus promoter, and the 
promoter is crucial for expression in tissue, but Sv40 is 
not a weak promoter; rather, it is a moderately potent 
promoter. 
Dr. Merriek. You have also found higher transfection i
the left ventricle than in the right ventricle. Do you have 
a W theories to explain this? 
Dr. Brauner. A relationship may exist between the 
magnitude of expression and the absolute quantity of 
perfusate to the respective tissue. However, the literature 
suggests that the right ventricle gets transduced less even 
with local injection, which is hard to explain. I really do 
not know why that is happening. 
Dr. Merrick. Finally, TGF-/31 has known neoplastic and 
fibroblastic effects. Do you have any concerns that this 
cytokine may actually increase the risk of graft arterioscle- 
rosis? 
Dr. Brauner. That question has been addressed specif- 
ically in a study (by Qin and associates sS) in which 
nonperfused neonatal mouse hearts were implanted in the 
ear pinnae of genetically identical mice and survived for 
long periods. The hearts were injected with TGF-/31- 
encoding plasmid. The authors looked specifically for 
growth factor effects of TGF-/31, such as intimal prolifer- 
ation "and fibrosis, and they did not find any. We know of 
no other reports of cardiac gene transfer with TGF-/31. 
We did not have a long enough survival time to look at 
that, but it is still a relevant concern. 
Dr. Robert C. Robbins (Stanford, Calif.). I think it is a 
good idea to look at either fluorescein labeling or isotope 
labeling to try to find your gene. At last year's meeting a 
paper about methodology was presented by a group from 
Seattle. What about results? Have you evaluated allograff 
survival using these methods? 
Dr. Brauner. I expected this question to come up. If the 
question is, does the technique prolong allograff survival, 
the answer is yes, both genes do. However, this is prelim- 
inary information, and we will have to wait for final 
results. 
Dr. Robbins. How much does it prolong survival? We 
are doing similar experiments atStanford looking at gene 
therapy at different argets, such as intracellular adhesion 
molecule (ICAM), and we are seeing prolongation i a rat 
model. I would be interested to hear the length of 
allograft survival in a rabbit model. 
Dr. Brauner. The problem with this first-generation 
virus is the limited time course of expression. The proba- 
ble reason is that some viral proteins are produced by this 
virus and expressed at the cell surface, eliciting an im- 
mune response. It is unlikely that prolongation of graft 
survival would extend beyond the time course of infection 
of the virus. Basically, if rejection occurs after more than 
10 days in untreated animals, it may not be a good model 
for such a study. If rejection in controls occurs in 6 to 7 
days, as is the case in this rabbit model, then one may 
observe a consistent and significant prolongation of sur- 
vival to the time of expression of the virus, which is about 
11 days or even longer. 
Dr. Robbins. I think this points out one of the limita- 
tions of this methodology. 
Dr. Brauner. Yes, but one should not give up, because 
better vectors are being constructed all the time. Actually, 
only 3 months ago a vector that is deleted of all viral 
proteins was reported (by Fisher and associates 22) at the 
Institute of Human Gene Therapy in Philadelphia. This is 
very promising, because itwill probably extend expression, 
while other research is going on as well. 
